



RESULTS FOR THE SECOND QUARTER, 2019

- FOLLOWING THE FAILURE OF OUR APPLICATION FOR A EUROPEAN SUBSIDY, ONE OF OUR SHAREHOLDER COMMITS TO RAISE THE BUDGET FOR PROOF OF EFFICACY
- CC & C RECEIVES DELIVERANCE OF ITS PATENT TO JAPAN AND THE USA

Arles, July 10, 2019 - CELL CONSTRAINT & CANCER, a company specializing in the treatment of pancreatic cancer with mechanical signals, presents its review of the past period, as well as its strategic priorities for the next quarter.

PROOF OF EFFICACY: DESPITE THE FET-OPEN REJECTION, THE CALENDAR IS MAINTAINED

On June 20th, we received the notification of rejection of our grant application for the European call Future Emerging Technologies (FET-Open). It was supposed to fund our Proof of Efficacy experiment, that is, the experimental proof that our method can reduce the volume of human pancreatic tumors grafted into the mouse pancreas. This is obviously a great disappointment, following the withdrawal of our correspondent from Stanford University, cutting short hopes for mounting the experiment in the United States, then a previous refusal to our first application at this FET-Open call, 10 months ago. The first contacts with European partners were initiated in April 2017. After two years of efforts, our funding strategy through collaborations with public laboratories is still not fruitful. Yet, unanimously, our file was better constructed, better argued, and responded to the remarks made against the first file. This was not the opinion of the jury.

First turnaround: Alain Couvineau, INSERM researcher (Bichat, Paris), internationally recognized for his expertise on digestive cancers and the main academic partner in the consortium set up for this European call, announces his intention to start feasibility studies on 3D cell cultures, to move forward despite our failure, on the budget from his laboratory.

Second turnaround: a few days later, **our new shareholder, TOD Finances, commits to raise the necessary funds to mount this Proof of Efficiency.** Various modalities are under study: optimization of the French Research Tax Credit (CIR), pre-financing of the CIR, issuance of (non-dilutive) bonds for other "major accounts" investors, current account operations. The budget will be smaller than on a European grant, but will allow to go to the end and maintain the planned schedule: feasibilities in 2020, animal testing in 2021, mainly operated by the teams of Pr. Couvineau.

We reaffirm the validity of our hypotheses, the scientific interest and the opportunity for patients to explore the effectiveness of our method in an animal model. This double signal of support, academic and financial, reinforces us and will allow us to use all the work done since 2 years: drafting of a solid protocol of experimentation, identification of the principal risks, optimization of the financing strategies.

The main directions are currently being discussed with various current and potential academic partners, and will be submitted to the deliberations of our next Strategic Committee to be held on July 16th. A budgeted experimental plan and a financing plan will be submitted to the next Strategic Committee in September for an immediate start of the first organoid studies. The willingness to hire a research engineer in September is still relevant.

REGIONAL GRANT PIA3: WORK IN PROGRESS

Together with our scientific partner in Marseilles CERIMED, we are making progress in the definition of a parallel experimental protocol to the Proof of Efficacy: biodistribution of nanoparticles in mice after injection, effective measurement of the pressure exerted to the interior of the tumor, test of several pressures applied to a tumor grafted subcutaneously in mice. Expected date of testing: Summer 2020

DELIVERANCE OF OUR PATENT FOR JAPAN AND THE UNITED STATES

Filed in July 2014, our patent was issued in Japan, of which we were notified on June 17, 2019, and in the United States, with a notification on July 5, 2019. This is good news for our finances, patents fees being an important part of our expenses each year. This delivery guarantees that we will have the exclusivity of our technique (on the territories in question) in the treatment of cancer until 2034. All that remains is to obtain the delivery at the European level, which is still under study at the European Patent Office.

Next appointment: September 30, 2019

Find all the information on CELL CONSTRAINT & CANCER:

<http://new.cellconstraintcancer.com/>



About CELL CONSTRAINT & CANCER

Founded in 2009 by Rémy BROSSEL, medical oncologist and physicist, CELL CONSTRAINT & CANCER develops innovative treatments based on [physical oncology](#), complementary to current approaches in oncology. Addressing primarily non-metastatic non-operable tumors, such as cancer of the pancreas, brain, or liver, the company published in May 2016 a proof of concept of slowing the growth of an in vivo grafted cancer tumor, by the action of mechanical signals (read our article: [Mechanical signals inhibit growth of a grafted tumor in vivo: Proof of Concept](#)).

Major partnerships (CNRS, INSERM) and the support of its shareholders since its beginning allow us today to initiate a new phase of experiments on animals intended to provide Proof of Efficacy of this technology on unmet medical needs.

CONTACTS

Press Relations - Shareholders & Investors Relations

Barthélémy BROSSEL

Tél. : [+33 \(0\)6 50 22 79 64](tel:+330650227964)

E-mail : barth.brossel@gmail.com